Genialis Inc. and Debiopharm SA have entered into an agreement to define and discover biomarkers within the DNA damage repair (DDR) biology space to predict the clinical benefit of one or more drugs in Debiopharm’s pipeline.

Genedit Inc. has entered into a multiyear collaboration and license agreement with Genentech Inc., a member of the Roche Group, to use Genedit's Nanogalaxy platform to discover and develop novel hydrophilic nanoparticles to deliver Genentech's nucleic acid-based medicines for treatment of autoimmune disease.

N4 Pharma plc’s subsidiary Nanogenics Ltd. has signed a contract to start the formulation and sequence selection work to prepare its ECP-105 product for testing in preclinical studies.

Abbvie Inc. and Umoja Biopharma Inc. have announced two exclusive option and license agreements to develop multiple in situ generated chimeric antigen receptor (CAR)-T cell therapy candidates in oncology using Umoja's proprietary Vivovec platform.

Remix Therapeutics Inc. has closed a $60 million financing to advance its lead program, REM-422, into the clinic and for further advancement of a pipeline of RNA processing targeted therapeutics.